Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt–Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
To date, cerebrospinal fluid analysis, particularly protein 14-3-3 testing, presents an important approach in the identification of Creutzfeldt-Jakob disease cases. However, one special point of criticism of 14-3-3 testing is the specificity in the differential diagnosis of rapid dementia. The constant observation of increased cerebrospinal fluid referrals in the national surveillance centres over the last years raises the concern of declining specificity due to higher number of cerebrospinal fluid tests performed in various neurological conditions. Within the framework of a European Community supported longitudinal multicentre study ('cerebrospinal fluid markers') we analysed the spectrum of rapid progressive dementia diagnoses, their potential influence on 14-3-3 specificity as well as results of other dementia markers (tau, phosphorylated tau and amyloid-β(1-42)) and evaluated the specificity of 14-3-3 in Creutzfeldt-Jakob disease diagnosis for the years 1998-2008. A total of 29 022 cerebrospinal fluid samples were analysed for 14-3-3 protein and other cerebrospinal fluid dementia markers in patients with rapid dementia and suspected Creutzfeldt-Jakob disease in the participating centres. In 10 731 patients a definite diagnosis could be obtained. Protein 14-3-3 specificity was analysed for Creutzfeldt-Jakob disease with respect to increasing cerebrospinal fluid tests per year and spectrum of differential diagnosis. Ring trials were performed to ensure the comparability between centres during the reported time period. Protein 14-3-3 test specificity remained high and stable in the diagnosis of Creutzfeldt-Jakob disease during the observed time period across centres (total specificity 92%; when compared with patients with definite diagnoses only: specificity 90%). However, test specificity varied with respect to differential diagnosis. A high 14-3-3 specificity was obtained in differentiation to other neurodegenerative diseases (95-97%) and non-neurological conditions (91-97%). We observed lower specificity in the differential diagnoses of acute neurological diseases (82-87%). A marked and constant increase in cerebrospinal fluid test referrals per year in all centres did not influence 14-3-3 test specificity and no change in spectrum of differential diagnosis was observed. Cerebrospinal fluid protein 14-3-3 detection remains an important test in the diagnosis of Creutzfeldt-Jakob disease. Due to a loss in specificity in acute neurological events, the interpretation of positive 14-3-3 results needs to be performed in the clinical context. The spectrum of differential diagnosis of rapid progressive dementia varied from neurodegenerative dementias to dementia due to acute neurological conditions such as inflammatory diseases and non-neurological origin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Measurement of Observer Agreement for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529310 · Cited by 81,148 · cited 1×
“Agreement was estimated according to Landis and Koch (1977): perfect if kappa 40.8, substantial if 0.85 kappa4 0.6, moderate if 0.65 kappa4 0.4, fair if 0.45 kappa4 0.2, slight if 0.25 kappa 4 0, poor if kappa 50 (Supplementary material).”
MethodInfluentialUpdated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease
Zerr, I., Kallenberg, K., Summers, D. M., Romero, C., Taratuto, A., Heinemann, U., Breithaupt, M., Varges, D., Meissner, B., Ladogana, A., et al. (2009) · Brain · doi:10.1093/brain/awp191 · Cited by 916
Self-citationImproved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724 · cited 1×
“The combined measurement of tau and amyloid b1–42 in CSF has proven diagnostic accuracy for Alzheimer’s disease (Hulstaert et al., 1999).”
BackgroundHsich, G., Kenney, K., Gibbs, C. J., Lee, K. H., & Harrington, M. G. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609263351303 · Cited by 660 · cited 3×
“Protein 14-3-3 analysis Protein 14-3-3 was tested in CSF by western blot according to previously published protocols (Hsich et al., 1996; Zerr et al., 1998).”
BackgroundMethodMasters, C. L., Harris, J. O., Gajdusek, D. C., Gibbs, C. J., Bernoulli, C., & Asher, D. M. (1979) · Annals of Neurology · doi:10.1002/ana.410050212 · Cited by 629 · cited 3×
“…Jean-Louis Laplanche,11 Katell Peoc’h,11 Gabi Schelzke,1 Andre Karch,1 Cornelia M. van Duijn12 and Inga Zerr1 1 Department of Neurology, National Reference Centre for Transmissible Spongiform Encephalopathies, Georg-August-University, 37075 Göttingen, Germany 2 Department of Neurology,…”
BackgroundSporadic and familial CJD: classification and characterisation
Gambetti, P., Kong, Q., Zou, W., Parchi, P., & Chen, S. G. (2003) · British Medical Bulletin · doi:10.1093/bmb/66.1.213 · Cited by 569 · cited 3×
“BRAIN A JOURNAL OF NEUROLOGY Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt–Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years Katharina Stoeck,1 Pascual Sanchez-Juan,2 Joanna Gawinecka,1 Alison Green,3 Anna Ladogana,4 Maurizio Pocchiari,4 Raquel Sanchez-Valle,5 Eva Mit…”
BackgroundAnalysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease
Zerr, I., Pocchiari, M., Collins, S., Brandel, J. P., de Pedro Cuesta, J., Knight, R. S. G., Bernheimer, H., Cardone, F., Delasnerie-Lauprêtre, N., Cuadrado Corrales, N., et al. (2000) · Neurology · doi:10.1212/wnl.55.6.811 · Cited by 481
Self-citationZerr, I., Bodemer, M., Gefeller, O., Otto, M., Poser, S., Wiltfang, J., Windl, O., Kretzschmar, H. A., & Weber, T. (1998) · Annals of Neurology · doi:10.1002/ana.410430109 · Cited by 456
Self-citationSich, G. A. H., Enney, K. I. K., Ibbs, C. L. J. G., Ee, K., & Arrington, G. H. (1996) · Cited by 380
Collins, S. J. (2006) · Brain · doi:10.1093/brain/awl159 · Cited by 338 · cited 1×
“…specificity; neurodegeneration; differential diagnosis in dementia Introduction The clinical diagnosis of Creutzfeldt–Jakob disease is based on clinical syndrome and results of established paraclinical tests (EEG, CSF analysis and cranial MRI) (Zerr et al., 2000a, 2009; Collins et al., 2006).”
Background
Cited by
A clinicopathological approach to the diagnosis of dementia
Elahi, F. M., & Miller, B. L. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.96 · Cited by 412
Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease
Hermann, P., Appleby, B., Brandel, J.-P., Caughey, B., Collins, S., Geschwind, M. D., Green, A., Haïk, S., Kovacs, G. G., Ladogana, A., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30477-4 · Cited by 361
Self-citationLewczuk, P., Riederer, P., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramirez, A., Parnetti, L., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 307
Self-citationExpression of Regulatory Proteins in Choroid Plexus Changes in Early Stages of Alzheimer Disease
Krzyzanowska, A., García-Consuegra, I., Pascual, C., Antequera, D., Ferrer, I., & Carro, E. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000181 · Cited by 42
“Furthermore, the detection of 14-3-3 in the CSF represents an important approach in the identification of Creutzfeldt-Jakob disease (40, 41).”
MethodCystatin F is a biomarker of prion pathogenesis in mice
Nuvolone, M., Schmid, N., Miele, G., Sorce, S., Moos, R., Schori, C., Beerli, R. R., Bauer, M., Saudan, P., Dietmeier, K., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171923 · Cited by 25
“0051, Student’s t test), in line with the more rapid clinical course [33,34].”
ResultSelf-citation
Metadata
- Authors
- Stoeck, K., Sanchez-Juan, P., Gawinecka, J., Green, A., Ladogana, A., Pocchiari, M., Sanchez-Valle, R., Mitrova, E., Sklaviadis, T., Kulczycki, J., Slivarichova, D., Saiz, A., Calero, M., Knight, R., Aguzzi, A., Laplanche, J.-L., Peoc’h, K., Schelzke, G., Karch, A., van Duijn, C. M., & Zerr, I.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-09-25
- Volume
- 135
- Issue
- 10
- Pages
- 3051-3061
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2115197326
- Cited by
- 161
- References
- 38
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt–Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. https://app.cochat.ai/papers/10.1093/brain/aws238
- The paper
- Stoeck, K., Sanchez-Juan, P., Gawinecka, J., Green, A., Ladogana, A., Pocchiari, M., Sanchez-Valle, R., Mitrova, E., Sklaviadis, T., Kulczycki, J., Slivarichova, D., Saiz, A., Calero, M., Knight, R., Aguzzi, A., Laplanche, J.-L., Peoc’h, K., Schelzke, G., Karch, A., . . . Zerr, I. (2012). Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt–Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain. https://doi.org/10.1093/brain/aws238
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.